Polymer Nanofiber-Embedded Microchips for Detection, Isolation, and Molecular Analysis of Single Circulating Melanoma Cells

Confined to one cell: A method to detect and isolate single circulating melanoma cells (CMCs; see figure) has been produced by integrating a polymer‐nanofiber‐embedded nanovelcro cell‐affinity assay with a laser microdissection (LMD) technique. This method is able to separate CMCs from normal white...

Full description

Saved in:
Bibliographic Details
Published inAngewandte Chemie International Edition Vol. 52; no. 12; pp. 3379 - 3383
Main Authors Hou, Shuang, Zhao, Libo, Shen, Qinglin, Yu, Juehua, Ng, Charles, Kong, Xiangju, Wu, Dongxia, Song, Min, Shi, Xiaohong, Xu, Xiaochun, OuYang, Wei-Han, He, Rongxian, Zhao, Xing-Zhong, Lee, Tom, Brunicardi, F. Charles, Garcia, Mitch André, Ribas, Antoni, Lo, Roger S., Tseng, Hsian-Rong
Format Journal Article
LanguageEnglish
Published Weinheim WILEY-VCH Verlag 18.03.2013
WILEY‐VCH Verlag
Wiley Subscription Services, Inc
EditionInternational ed. in English
Subjects
Cancer
cancer diagnosis
Cell Line, Tumor
Cell Separation
Circulating
circulating tumor cells
Erythrocytes - cytology
Humans
Lactic Acid - chemistry
Lasers
Melanoma
Melanoma - diagnosis
Melanoma - metabolism
Microfluidic Analytical Techniques
Mutation
Mutations
Nanofibers - chemistry
Nanostructure
Neoplastic Cells, Circulating - chemistry
Neoplastic Cells, Circulating - metabolism
Personalized
Polyglycolic Acid - chemistry
Polymers
Polymers - chemistry
Progressions
Proto-Oncogene Proteins B-raf - genetics
Proto-Oncogene Proteins B-raf - metabolism
Single-Cell Analysis
White blood cells
Online AccessGet full text

Cover

More Information
Summary:Confined to one cell: A method to detect and isolate single circulating melanoma cells (CMCs; see figure) has been produced by integrating a polymer‐nanofiber‐embedded nanovelcro cell‐affinity assay with a laser microdissection (LMD) technique. This method is able to separate CMCs from normal white blood cells (WBCs) and sequence individual cells for a specific mutation related to cancer progression, allowing for more personalized cancer therapy.
Bibliography:ArticleID:ANIE201208452
istex:8EF787F65A9E7C76851DA01E8A4EAE80AB4C441D
ark:/67375/WNG-JWMMZDL1-L
This research was supported by the National Institutes of Health (R21 CA151159 and R33 CA157396). Dr. F. Charles Brunicardi, Dr. Antoni Ribas, Dr. Roger S. Lo, and Dr. Hsian-Rong Tseng are members of UCLA Josson Comprehensive Cancer Center. They acknowledge generous support from JCCC and promotion of the collaboration.
National Institutes of Health - No. R21 CA151159; No. R33 CA157396
This research was supported by the National Institutes of Health (R21 CA151159 and R33 CA157396). Dr. F. Charles Brunicardi, Dr. Antoni Ribas, Dr. Roger S. Lo, and Dr. Hsian‐Rong Tseng are members of UCLA Josson Comprehensive Cancer Center. They acknowledge generous support from JCCC and promotion of the collaboration.
These authors contributed equally to the work.
ObjectType-Article-1
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-2
content type line 23
ISSN:1433-7851
1521-3773
1521-3773
DOI:10.1002/anie.201208452